Since Crolm's original description (l) of a granuh)matous disorder involving the terminal ileum, distinct from ileocecal tnherculosis, little has been done to elucidate its cause. This is both curious att(l unfortunate, for its distribution, i)athologic features and patterns of recurrence suggest numerous possibilities for investigation. The presence of grantdomas has invited comparison with disorders exhibiting similar lesions such as tuberculosis, herylliosis, the deep ntycoses and sarcoidosis, but no convincing l)arallels have emerged.
Speculation has in the main centered around either an infectious or an immune origin. Attempts to isolate an infectious agent have been unrewarding but limited, I)eing confined largely to mycol)acterium tuberculosis and certain viruses (2) . Although there is little to suggest an immune etiology for this disorder, graimlomas may in some situations constitute morphologic evidence of an immune response. The granulonlatous reaction to tubercle bacilli and many fungi has long been nnderstood as a manifestation of delayed hypersensitivity; more recently the tissue response in schistosomiasis has been shown to have a similar basis (3). Still, no organism capable of initiating such an immune response has been found in affected tissues, nor have tissues exhibiting granulomas been shown to contain antigens capable of eliciting an immune response in patients with Crohn's disease (4) .
Although the comparison with sarcoidosis, another chronic granulomatous disorder of unknown cause, is somewhat strained, the recent finding that anonymous mycobacteria could be cultured from the tissues of such patients with mycobacteriophage-neutralizing antisera has obvlous potential relevance (5, 6) . It would therefore be of interest to know whether infection by such organisms was more fre-quent in individuals with Crohn's disease than in the population at large. If true, such patients might be expected to exhibit either delayed cutaneous reactions or humoral antibodies to these mycobacterial antigens.
MATERIALS AND METHODS
Twenty-two patients with Crohn's disease were investigated for the presence of precipitins or delayed cutaneous reactions to atypical mycobacterial antigens of Runyon's Groups I, II and III as well as PPD. Only patients with typical radiologic or histologic features were included. Skin test controls were derived from two sources: (1) student nurses at the University of Michigan who formed part of a study carried out by the Pulmonary Disease Section of the Department of Medicine, and (2) white navy recruits, aged 17-21 years, tested as part of the USPHS-USN cooperative skin test program (7) . The atypical mycobacterial antigens were obtained from the National Communicable Disease Center and contained 0.0001 mg/0.l ml (skin test dose). Standard intermediate strength PPD was utilized as an additional control. All skin tests were carried out on the volar aspect of the forearm and were read at 48 hr. At this time the diameter of any induration was measured. No patients were on corticosteroids or immunosuppressives. Before the skin tests were applied, blood was obtained for double gel diffusion studies by the standard microscopic slide technic using the same antigens used for skin testing.
RESULTS

Control Group
The USPHS-USN cooperative skin test program tested 14,261 Michigan naval recruits, aged 17-21, with PPD-S and PPD-B in a manner identical to that employed in this study. Induration of 4 mm or more at 48 hr in response to PPD-S was found in 4.4% while 15.5% manifested 4 mm or more of induration upon being tested with PPD-B. The criteria for quantitating the dermal reactions were chosen simply to separate those who react to the test from those who do not. No other interpretation based upon magnitude of response was attempted.
Most reactions to PPD-B (Group II) probably represent cross reactions to still unidentified mycobacterial infections as do minimal (less than 10 mm) reactions to PPD-S. Therefore, one cannot use the results in our two control groups or our patient group to derive information concerning specific infection with a given mycobacterium; rather, one should use a general index of exposure to many mycobacterial antigens which is in fact the objective of this study.
In the nursing students, reactions of 5 mm or more of induration were found in 3.6~ (of 368) tested with PPD-S; 20.1~o (of 167) tested with PPD-B (Group II) and 51.1~o (of 201) tested with PPD-G (Group III). The navy recruits were not tested with PPD-G. These results are summarized in Table 1 .
Test Group
Eighteen percent of the patients with Crohn's disease (4 of 22) exhibited 5 mm or more of induration to PPD-S. None of the 22 reacted to PPD-Y (Group I) while 13.6% (3 of 22) responded with 5 mm or more of induration to both PPD-B and PPD-G. None of the 14 patients whose sera were tested had precipitating antibodies to any of the four. antigens as measured by double gel diffusion. The results of the studies carried out in the patient group are tabulated in Table 2 . That a similar situation might exist in patients with Crohn's disease is a possibility worth considering. Although sarcoidosis and Crohn's disease appear to be entities distinct from one another, certain points of similarity do exist. They are both chronic granulomatous disorders o£ obscure origin, and anergy for delayed hypersensitivity has been associated with both. While firmly established for sarcoidosis, such anergy continues to be debated in the case of Crohn's disease. The results of some studies support the existence of anergy (4) while others do not (10). The best controlled and most convincing study, that of Fletcher and Hinton (10), suggest that anergy is not characteristic of patients with Crohn's disease. It should be remembered, however, that even in sarcoidosis, anergy i~ not complete; some antigens continue to elicit delayed hypersensitivity reactions in a normal manner.
DISCUSSION
A further point of similarity between the two disorders is the recent finding that approximately one-half of patients with Crohn's disease develop a positive reaction to the Kveim antigen (I1). Previous studies of the Kveim reaction in Crohn's disease have been negative (4). Mitchell et al point out, however, that biopsies were not done and smaller amounts of test material were employed in the studies yielding negative results.
In view o[ these similarities between Crohn's disease and sarcoidosis and the finding of atypical mycobacterial species in the latter, it seemed worthwhile to determine whether patients with Croh~fs disease demonstrated more frequent cutaneous or serologic reactions to atypical mycobacterial antigens than controls.
The results of this study indicate that no increase in delayed cutaneous responses is present in such patients in comparison with control groups. Furthermore, no circulating antibodies could be demonstrated to these antigens by the double gel dig fusion technic.
Alternative interpretations of these resuits are possible. First, tissue involvement with atypical mycobacteria may not be characteristic of patients with Crohn's disease. Dermal reactivity would likely be present if such were the case. However, mycobacteria other than the ones utilized in this study might be responsible. If so, one nlnst assLlnle they are not cross-reactive with Runyon's Groups I, II or III or standard PPD. There is also no certainty that such antigens existing in a lysogenous state are immunogenic. Second, these results would be consistent with a state of anergy to the antigens employed. This possibility cannot be excluded although the results of Fletcher and Hintmfs study would appear to make this unlikely. The recent demonstration that patients with Crohn's disease are less susceptible to primary sensitization with 2,4 dinitrochlorobenzene than normal controls (12) may, however, alter this belief. It may be that while established delayed hypersensitivity is not interfered with, there is an impairment in the ability to acquire such sensitivity af'ter the advent o1! Crohn's disease.
Although the results of the present study do not supl)ort a role for atypical mycobacterial organisms of Runyon's Groups I, II or III in the pathogenesis of Crohn's disease, the possibility that some obscure my. cobacterial species ntay play such a role shonld not lie prematurely abandoned. It is perhaps noteworthy that azulfidine may have a 1)eneficial effect on the course of Crohn's disease. This ntedication contains a 5-amino salicylic acid moiety as well as a sulfapyridine molecule similar to the tuberculostatic drug PAS. Sulphones, analognes of p-aminobenzoic acid, sulphonamides and aminosalicylic acid are effective in mycobacterial disorders such as leprosy (13).
It would be worthwhile to attempt to isolate atypical mycobacterial organisms from the affected tissues of patients with Crohn's disease, utilizing antimycobacteriophages in the culture system.
